Lung Cancer Clinical Trials in Chicago

Showing 81-100 of 358 trials

Evaluating a Fasting-mimicking Diet in Combination With Immunotherapy in Patients With Non-small Cell Lung Cancer

NCT06671613

The purpose of this study is to learn the effects of fasting on cancer cells while you get maintenance treatment.

VA Office of Research and Development66 participantsStarted Oct 2025

Long Beach, California, United States • Chicago, Illinois, United States • Indianapolis, Indiana, United States +1 more locations

RECRUITINGPHASE1/PHASE22.2 miles

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

NCT04665206

This is an open-label, dose escalation and expansion study to evaluate the safety, tolerability, PK, and biological activity of VT3989 administered, alone or in combination, once daily in patients with mesothelioma and/or metastatic solid tumors that are resistant to standard therapy or for which no effective standard therapy is available.

Solid Tumor, AdultMesotheliomaNSCLC

Vivace Therapeutics, Inc336 participantsStarted Mar 2021

San Francisco, California, United States • Chicago, Illinois, United States • Boston, Massachusetts, United States +9 more locations

Evaluating a Fasting-mimicking Diet in Combination With Immunotherapy in Patients With Non-small Cell Lung Cancer

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

Lung Cancer Trials in Other Cities

To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

Prolonged Air Leak (PAL) Autologous Blood Patch Intervention Trial

Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments

Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).

Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer

Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors

A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy

Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors

Gilteritinib for the Treatment of ALK NSCLC

Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression

An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors

A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors

A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)

Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations

QUILT-3.038: Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEA

A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Other Conditions in Chicago